Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2007 1
2009 3
2010 6
2011 15
2012 16
2013 9
2014 13
2015 4
2016 5
2017 5
2018 8
2019 6
2020 4
2021 3
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS Investigators. Hart RG, et al. N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766772 Free article. Clinical Trial.
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, Ameriso SF, Endres M, Lutsep H, Messé SR, Spence JD, Nedeltechev K, Perera K, Santo G, Olavarria V, Lindgren A, Bangdiwala S, Shoamanesh A, Berkowitz SD, Mundl H, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators. Kasner SE, et al. Lancet Neurol. 2018 Dec;17(12):1053-1060. doi: 10.1016/S1474-4422(18)30319-3. Epub 2018 Sep 28. Lancet Neurol. 2018. PMID: 30274772 Free PMC article. Clinical Trial.
[Takotsubo cardiomyopathy and cerebral infarction].
Kato Y, Takeda H, Furuya D, Deguchi I, Tanahashi N. Kato Y, et al. Among authors: deguchi i. Rinsho Shinkeigaku. 2009 Apr;49(4):158-66. doi: 10.5692/clinicalneurol.49.158. Rinsho Shinkeigaku. 2009. PMID: 19462813 Review. Japanese.
Intractable Neurosarcoidosis Effectively Treated with Infliximab.
Sano H, Deguchi I, Fukuoka T, Hayashi T, Uchino A, Adachi J, Yasuda M, Takao M, Tanahashi N. Sano H, et al. Among authors: deguchi i. Intern Med. 2016;55(7):811-4. doi: 10.2169/internalmedicine.55.5506. Epub 2016 Apr 1. Intern Med. 2016. PMID: 27041170 Free article.
Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke.
Deguchi I, Mizuno S, Kohyama S, Tanahashi N, Takao M. Deguchi I, et al. J Stroke Cerebrovasc Dis. 2018 Jan;27(1):61-67. doi: 10.1016/j.jstrokecerebrovasdis.2017.07.033. Epub 2017 Sep 1. J Stroke Cerebrovasc Dis. 2018. PMID: 28867523
YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy).
Aoki J, Kimura K, Morita N, Harada M, Metoki N, Tateishi Y, Todo K, Yamagami H, Hayashi K, Terasawa Y, Fujita K, Yamamoto N, Deguchi I, Tanahashi N, Inoue T, Iwanaga T, Kaneko N, Mitsumura H, Iguchi Y, Ueno Y, Kuramoto Y, Ogata T, Fujimoto S, Yokoyama M, Nagahiro S; YAMATO Study Investigators. Aoki J, et al. Among authors: deguchi i. Stroke. 2017 Mar;48(3):712-719. doi: 10.1161/STROKEAHA.116.015042. Epub 2017 Jan 24. Stroke. 2017. PMID: 28119434 Clinical Trial.
83 results